eledon-logo-1230.png
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
29 oct. 2024 07h46 HE | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
eledon-logo-1230.png
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
29 oct. 2024 07h45 HE | Eledon Pharmaceuticals, Inc.
Eledon Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of Regimen Following Islet Transplantation
eledon-logo-1230.png
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
11 sept. 2024 16h05 HE | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
eledon-logo-1230.png
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
04 sept. 2024 07h00 HE | Eledon Pharmaceuticals, Inc.
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants
eledon-logo-1230.png
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
14 août 2024 17h21 HE | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
eledon-logo-1230.png
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
29 juil. 2024 07h00 HE | Eledon Pharmaceuticals, Inc.
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
eledon-logo-1230.png
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
02 juil. 2024 16h05 HE | Eledon Pharmaceuticals, Inc.
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
eledon-logo-1230.png
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
03 juin 2024 16h01 HE | Eledon Pharmaceuticals, Inc.
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
eledon-logo-1230.png
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
09 mai 2024 07h30 HE | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
eledon-logo-1230.png
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
09 mai 2024 07h00 HE | Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at ATC 2024